Cingulate(CING) - 2025 Q4 - Annual Report

Market Potential - The ADHD treatment market in the US is estimated to have approximately 100 million annual prescriptions, with a potential 1% market share representing $250 to $300 million in annual revenue[17]. - CTx-2103, targeting the anxiety market, is designed for once-daily administration and is part of a market that generated over $1 billion in sales in 2025[19]. - Total prescriptions of extended-release stimulants in the U.S. grew by 10.2% annually for the 12 months ended September 2025, with approximately 96 million stimulant prescriptions written[38][46]. - Approximately 90% of all ADHD medication prescriptions are stimulants, with four main medications dominating 92% of the extended-release stimulant market[46]. - Recent stimulant medications have captured only about 2.0% of total ADHD prescriptions in the U.S. in 2025, indicating a significant unmet need for effective treatments[54]. Product Development - CTx-1301 and CTx-1302 are designed to provide a near immediate onset of action within 30 minutes and eliminate the need for booster doses, addressing key shortcomings of current therapies[18]. - The NDA for CTx-1301 was submitted to the FDA on July 31, 2025, with a PDUFA target action date of May 31, 2026[23]. - A Phase 3 study of CTx-1301 in adults showed significant improvements in secondary endpoints, although the primary efficacy endpoint did not achieve statistical significance[22]. - The company plans to initiate the clinical plan for CTx-1302 pending additional capital resources[28]. - CTx-2103's formulation study demonstrated a triple release of buspirone, which is critical for the design of clinical studies for filing an IND[29]. - The clinical development program includes two Phase 1/2 studies and a Phase 3 trial, with the latter completed in June 2023[86]. - CTx-1301 is designed to provide onset-of-action within 30 minutes and entire active-day efficacy, with a release profile of 35%-45%-20% for the total daily dose[70]. - CTx-1301's unique trimodal release profile is engineered to provide rapid symptom relief and maintain efficacy throughout the day, addressing common issues with current ADHD treatments[73]. - CTx-1301 demonstrated consistent dose-dependent efficacy in improving ADHD symptoms, with the 37.5mg dose showing the largest effect size and symptom reduction in a Phase 3 study involving 103 subjects aged 6-17[103]. - CTx-1302 is expected to be the first true once-daily dextroamphetamine tablet for ADHD, with a release profile designed to provide therapeutic efficacy within 30 minutes[110]. - The clinical development program for CTx-1302 includes approximately 100 patients in Phase 1/2 studies and around 500 patients in Phase 3 trials[111]. - CTx-2103 aims to be the first once-daily formulation of buspirone for anxiety treatment, addressing the challenges of multiple daily dosing associated with current treatments[118]. Regulatory and Compliance - The FDA has assigned a PDUFA target action date of May 31, 2026, for the review of CTx-1301's NDA[35]. - The FDA has provided guidance on the regulatory pathway for CTx-2103, indicating potential approval under the 505(b)(2) pathway, which typically requires fewer resources[122]. - The FDA requires that sponsors of clinical trials register and disclose certain clinical trial information on www.clinicaltrials.gov, including results after completion[182]. - Following drug approval, manufacturers are subject to ongoing FDA regulation, including monitoring and record-keeping activities, and must comply with cGMP requirements[183]. - The FDA may issue a complete response letter (CRL) if the NDA is not approved in its current form, detailing deficiencies that need to be addressed[162]. - The FDA may impose restrictions on product distribution and prescribing through a risk evaluation and mitigation strategy (REMS) plan[164]. - The submission of an IND must become effective within 30 days unless the FDA raises concerns, which could delay the start of clinical trials[147]. - The FDA may not approve an ANDA or 505(b)(2) NDA until any applicable period of non-patent exclusivity for the referenced RLD has expired, which includes a five-year period of non-patent marketing exclusivity for the first applicant to gain NDA approval for a new chemical entity[174]. - The FDCA provides three years of marketing exclusivity for a NDA if new clinical investigations are deemed essential for approval, covering only the conditions of use associated with those investigations[175]. - The FDA will conduct a pre-approval inspection of manufacturing facilities to ensure compliance with cGMPs before approving an NDA[159]. - Changes to the manufacturing process are strictly regulated and often require prior FDA approval or notification[186]. - The FDA may withdraw drug approval if compliance with regulatory requirements is not maintained or if new problems arise post-market[187]. Intellectual Property - The company has received a first European patent for CTx-1301, providing patent protection until 2042[24]. - The company holds six patents and two patent applications in the United States, with additional patents and applications in various countries, expiring between 2031 and 2043[130]. - The patent for the "Delayed Prolonged Drug Delivery" formulation is set to expire in March 2031, while other patents related to sustained release formulations extend to November 2035 and beyond[131][132]. - The company intends to strengthen its intellectual property portfolio to protect its PTR platform and product candidates from competitors[35]. - The company is focused on building its intellectual property portfolio, including trade secrets and proprietary know-how, to maintain a competitive edge in the ADHD market[133]. Financial Considerations - The cost of preparing and submitting an NDA is substantial, with application user fees currently over $3.24 million and an annual program fee of approximately $394,000[156]. - The company expects that some product candidates may require black box warnings as part of their labeling during the NDA review process[164]. - The Medicare program may reimburse self-administered drugs under Medicare Part D, which is administered by private plans[200]. - The Inflation Reduction Act of 2022 has reduced US government reimbursement for some drugs, indicating ongoing downward pressure on pharmaceutical reimbursements[202]. - Compliance with healthcare laws and regulations involves substantial costs, and violations may lead to significant penalties, including loss of eligibility for FDA approvals[206]. Market Strategy - The company aims to leverage its PTR platform to develop additional assets with the potential for $1 billion or more in peak annual sales[30]. - The company is evaluating opportunities to acquire or in-license additional assets to complement its portfolio and enhance value[35]. - The company intends to submit NDAs under the 505(b)(2) regulatory approval pathway, which may reduce some development burdens by referencing existing studies[143]. - The company must negotiate coverage and reimbursement decisions for its product candidates, which are influenced by existing branded drugs and clinical need[199]. - The company plans to enter into commercial supply agreements with additional manufacturers for its APIs in the future[128]. Safety and Efficacy - CTx-1301 patients experienced a 28.6% reduction in treatment emergent adverse events compared to Focalin XR[79]. - No serious treatment-emergent adverse events (TEAEs) were reported in the Phase 3 trials, indicating a favorable safety profile for CTx-1301[102]. - The Phase 1 food effect studies confirmed that CTx-1301 can be taken with or without food, with no serious treatment emergent adverse events reported[83]. - The Phase 3 study showed significant improvements in CGI-S scores for CTx-1301 compared to placebo, indicating notable treatment effects[86]. - The proprietary PTR drug delivery platform technology aims to eliminate the need for additional stimulant boosters, enhancing patient compliance[64].